Skip Navigation

Cardiovascular Research 2005 65(4):770-771; doi:10.1016/j.cardiores.2005.01.009
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Petrashevskaya, N. N.
Right arrow Articles by Schwarz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrashevskaya, N. N.
Right arrow Articles by Schwarz, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Peroxisome proliferator-activated receptor β/{delta}: a new antihypertrophic drug target?

Natalia N. Petrashevskaya* and Arnold Schwarz

Institute of Molecular Pharmacology and Biophysics, Department of Surgery, University of Cincinnati College of Medicine, G936 Cardiovascular Research Center, 231 Albert Sabin Way, Cincinnati, OH 45267-0529, United States

* Corresponding author. Tel.: +1 513 558 2374; fax: +1 513 558 1778. Email address: petrasnn{at}email.uc.edu

Received 6 January 2005; accepted 10 January 2005

See article by Planavila et al. [6] (pages 832–841) in this issue.

In the normal adult heart, plasticity of ATP production is provided by coordinated changes in the expression of genes involved in cellular fatty acid (FA) utilization and glucose oxidation. The phenotypes of acquired forms of heart failure in human and animal models are associated with energy substrate changes accompanying a reduced mitochondrial FA oxidative capacity and a shift to glucose metabolism, resembling the fetal metabolic program [1]. High glucose conditions, initially serving as a protective response to support contractile function, stimulate the production of angiotensin II (Ang II), a known pathological modulator of cardiac remodeling [2].

Peroxisome proliferator-activated receptors (PPARs) are gene regulatory systems that regulate the transcription of an array of genes involved in cellular fatty acid utilization pathways. PPARs are ligand-dependent transcription factors belonging to the nuclear receptor superfamily. They are designed to rapidly respond to fluctuating substrate and metabolic intermediates. They regulate pathways involved in FA utilization upstream to the transcriptional regulatory network including nuclear respiratory factors 1 and 2 and mitochondrial transcription factor A [3]. PPARs have 3 isoforms, {alpha}, β/{delta}, and {gamma}, that regulate lipid and glucose metabolism, participate in the regulation of cell growth and migration and in the control of oxidative stress and inflammation in the cardiovascular system [4,5]. Functional specificity among the PPARs is achieved by isoform-specific tissue distribution, ligands, and cofactor interaction. As shown by the paper by Planavila et al. [6] in this issue of Cardiovascular Research, there is a certain degree of functional overlap between PPAR{alpha} and β/{delta} in inhibition of cellular transduction pathways leading to cardiac hypertrophic remodeling.

In addition to conventional pharmacotherapy (angiotensin-converting enzyme inhibitors, β-adrenoreceptor blockers), selective PPAR{alpha} and {gamma} activators, partial agonists, or dual {alpha}/{gamma} activators may lead to interesting antihypertrophic cardiovascular therapies. However, potential applications of targeting these negative regulators, including PPARβ/{delta}, for complex therapies require vigorous verification of their role in adaptive and maladaptive remodeling and limitations in the prevention and treatment of left ventricular hypertrophy and heart failure.

PPAR{alpha}–PPAR{alpha} is a primary transcriptional regulator of fat metabolism in tissues with high FA oxidation rates such as heart, liver, kidney, and skeletal muscle. It regulates every step of cardiac FA utilization through the induction of target genes involved in fatty acid metabolism. Mice deficient in PPAR{alpha} have a reduced capacity for constitutive myocardial β-oxidation of medium and long chain fatty acids and a prolonged response to inflammatory stimuli and age-dependent myocardial fibrosis (for review see [3]). Deactivation of the PPAR{alpha} signaling pathway by MAP kinases, which are rapidly activated by diverse prohypertrophic mitogenic stimuli, is an early step in the downregulation of fatty acid oxidation (FAO) in the hypertrophied heart [7]. PPAR{alpha} ligands have been shown to reduce cardiac hypertrophy and inflammation by interfering with the nuclear factor (NF)-{kappa}B transactivation capacity through a direct protein–protein interaction with the p65 subunit [8]. Antihypertrophic activity of PPAR{alpha} activation interrupts other signaling events promoted by the hypertrophic inducer endothelin (ET) such as c-Jun N-terminal protein kinase activation, c-Jun phosphorylation, and c-Jun induction in cardiomyocytes. The PPAR{alpha} ligand, fenofibrate, inhibits ET-1 promoter activity, prepro-ET-1 mRNA expression, and hypertrophy in ET-1-stimulated cardiomyocytes [9].

PPAR{gamma}–Although PPAR{gamma} is expressed in the heart at levels much below that of PPAR{alpha} and PPARβ/{delta}, recent results suggest that the PPAR{gamma}-dependent pathway is involved in the hypertrophic response and inhibits the development of cardiac hypertrophy, counteracting diverse prohypertrophic signaling pathways. PPAR{gamma} may suppress the development of cardiac hypertrophy by antagonizing the activities of transcription factors such as AP-1, STAT3, and GATA4 [10, 11]. The thiazolidinediones, high-affinity ligands for PPAR{gamma}, inhibit Ang-II-induced cardiac hypertrophy in vitro and pressure overload-induced cardiac hypertrophy in vivo. Pressure overload induces more marked cardiac hypertrophy in heterozygous PPAR{gamma}-deficient mice than in wild-type mice [10]. However, the use of thiazolidinediones may be limited to patients with less advanced cardiovascular disease because PPAR{gamma} activators may trigger aggravation of heart failure as a consequence of their insulinomimetic action.

PPARβ/{delta}–The role of PPARβ/{delta} in the regulation of cardiac metabolism and signaling to downstream prohypertrophic pathways has been relatively unexplored (for review see [12]). CRE-lox-mediated, cardiomyocyte-restricted deletion of PPARβ/{delta} in mice downregulates constitutive expression of key FAO genes and decreases basal myocardial FAO. PPARβ/{delta}-deficient mice display cardiac dysfunction, progressive myocardial lipid accumulation, cardiac hypertrophy, and congestive heart failure [13].

The study by Planavila et al. [6] highlights the regulatory role of PPAR{delta} as an emerging player in the loss of substrate utilization flexibility in hypertrophied and failing heart. Treatment with the PPARβ/{delta} agonist L-165041 prevented the reduction in the transcript level of genes involved in lipid metabolism including muscle-type carnitine palmytoyltransferase determining the flux of mitochondrial β-oxidation and pyruvate dehydrogenase kinase 4 (PDK-4). PDK-4 is a suppressor of glucose oxidation via its inhibitory effect on the pyruvate dehydrogenase complex. The work of Planavila et al. [6] provides evidence that PPARβ/{delta} and PPAR{alpha} regulate overlapping sets of genes or superimposed pathways involved in cardiac hypertrophic remodeling. PPARβ{delta} is unlikely to compensate for PPAR{alpha} in all physiological reactions but represents a new negative regulator of cardiac hypertrophic remodeling that acts similar to PPAR{alpha} via suppression of the NF-{kappa}B prohypertrophic pathway. Planavila et al. [6] have demonstrated that L 165041, the selective PPARβ/{delta} activator, decreases LPS-stimulated NF-{kappa}B binding activity in H9c2 myotubes and enhances physical interaction between PPARβ/{delta} and the p65 subunit of NF-{kappa}B.

The findings by Planavila et al. [6] provide a new insight into several regulatory steps in response to growth signals and into the role of PPARβ/{delta} in this signaling network. It would be of interest to correlate changes in cardiac energetics caused by PPAR activation with suppression of the genes involved in glucose transport and utilization, which induces a diabetic state and secondarily may cause left ventricular hypertrophy similar to PPAR{gamma} agonists [14]. The identification of prohypertrophic stimuli leading to reduction in PPARβ/{delta} expression and hemodynamic characterization in long-term animal models are necessary to delineate therapeutic strategies specifically targeting PPARβ/{delta} in the treatment of cardiac hypertrophy and failure.


   References
Top
 References
 

  1. Goffart S., von Kleist-Retzow J.-C., Wiesner R.J. Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc. Res. (2004) 64:198–207.[Abstract/Free Full Text]
  2. Diep Q., Amiri F., Touyz R., Cohn J., Endelman D., Schiffrin E. PPAR{alpha} activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension (2002) 40:866–871.[Abstract/Free Full Text]
  3. Huss J.M., Kelly D.P. Nuclear receptor signaling and cardiac energetics. Circ. Res. (2004) 95:568–578.[Abstract/Free Full Text]
  4. Delerive P., DeBosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzales F.J., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcriptional factor NF-kappa B and AP-1. J. Biol. Chem. (1999) 274:32048–32054.[Abstract/Free Full Text]
  5. Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., et al. PPAR{alpha} and PPARβ/{delta}, but not PPAR{gamma} modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. (2003) 92:518–524.[Abstract/Free Full Text]
  6. Planavila A., Rodríquez-Calvo R., Jové M., Michalik L., Wahli W., Laguna J.C., et al. Peroxisome proliferator-activated receptor β/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. (2005) 65:832–841.[Abstract/Free Full Text]
  7. Barger P.M., Brandt J.M., Leone T.C., Weinhelmer C.J., Kelly D.P. Deactivation of peroxosome proliferator-activated receptor {alpha} during cardiac hypertrophic growth. J. Clin. Invest. (2000) 105:1723–1730.[Web of Science][Medline]
  8. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayma-Tomobe Y., Yamagushi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol. (2004) 43:1481–1488.[Abstract/Free Full Text]
  9. Irukayama-Tomobe Y., Miyauchi T., Sakai S., Kasuya Y., Ogata T., Takanashi M., et al. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-{alpha} partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation (2004) 109:904–910.[Abstract/Free Full Text]
  10. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., et al. Peroxisome proliferator-activated receptor {gamma} plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation (2002) 105:1216–1246.
  11. Wang Xing Li, Oosterhof J., Duarte N. Peroxisome proliferator-activated receptor {gamma} C161-T polymorphism and coronary artery disease. Cardiovasc. Res. (1999) 44:588–594.[Abstract/Free Full Text]
  12. Wang Y.-X., Lee C.H., Tiep S., Yo R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor {delta} activates fat metabolisms and prevents obesity. Cell (2003) 113:159–170.[CrossRef][Web of Science][Medline]
  13. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor {delta} deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nature (Med.) (2004) 10:1245–1250.[CrossRef][Web of Science][Medline]
  14. Hardt S.E., Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc. Res. (2004) 63:500–509.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
X. Sun, J. D. Ritzenthaler, X. Zhong, Y. Zheng, J. Roman, and S. Han
Nicotine Stimulates PPAR{beta}/{delta} Expression in Human Lung Carcinoma Cells through Activation of PI3K/mTOR and Suppression of AP-2{alpha}
Cancer Res., August 15, 2009; 69(16): 6445 - 6453.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. Han, J. D. Ritzenthaler, X. Sun, Y. Zheng, and J. Roman
Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} Induces Lung Cancer Growth via Peroxisome Proliferator-Activated Receptor Coactivator {gamma}-1{alpha}
Am. J. Respir. Cell Mol. Biol., March 1, 2009; 40(3): 325 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Han, J. D. Ritzenthaler, Y. Zheng, and J. Roman
PPAR{beta}/{delta} agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-{kappa}B signals
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1238 - L1249.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Petrashevskaya, N. N.
Right arrow Articles by Schwarz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrashevskaya, N. N.
Right arrow Articles by Schwarz, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?